D2 receptor occupancy under recommended and high doses of olanzapine.
Harvey
E J
EJ
Taylor
D M
DM
Flanagan
R J
RJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001569:Benzodiazepines; D002648:Child; D002675:Child, Preschool; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D012016:Reference Values; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015899:Tomography, Emission-Computed, Single-Photon
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine